Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
- 1 May 2009
- journal article
- review article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 5 (4), 433-443
- https://doi.org/10.2217/fon.09.24
Abstract
Androgen deprivation therapy with gonadotropin releasing-hormone (GnRH) receptor agonists provides the mainstay of endocrine treatment for advanced prostate cancer. Although effective, GnRH agonists induce an initial testosterone surge, which can cause painful and potentially dangerous clinical flare. Degarelix is a novel GnRH receptor blocker that provides immediate, profound and sustained testosterone reduction, without an initial surge. In a Phase III trial, degarelix and leuprolide showed similar long-term efficacy in maintaining testosterone levels of 0.5 ng/ml or less over 1 year, and induced significantly faster testosterone and prostate-specific antigen suppression. Degarelix was well tolerated; the most common side effects were mild/moderate injection-site reactions and hot flashes. Findings to date suggest that degarelix may make an important contribution to the treatment of prostate cancer.Keywords
This publication has 25 references indexed in Scilit:
- A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North AmericaJournal of Urology, 2008
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone AntagonistThe Journal of pharmacology and experimental therapeutics, 2006
- Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH AnaloguesEuropean Urology, 2004
- Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performanceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2004
- Gonadotropin-releasing-hormone-receptor antagonistsThe Lancet, 2001
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6Journal of Medicinal Chemistry, 2000